Citius pharmaceuticals, inc. reports fiscal full year 2021 financial results and provides business update

Cranford, n.j., dec. 15, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the fiscal full year ended september 30, 2021.
CTXR Ratings Summary
CTXR Quant Ranking